Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...

(Reuters) - Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...

In response to increased criticism of its pricing, Gilead Sciences has reached voluntary licensing deals with companies to make generic versions of its twice-yearly HIV medicine, lenacapavir ...

Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.

US pharmaceutical giant Gilead said Wednesday it had signed licensing deals with six generic drugmakers to produce and sell its HIV prevention medicine in lower-income countries. The announcement ...

Despite major advances in scientific innovation, access to care and growth of health systems, there are still millions of ...

Oct 2 (Reuters) - Gilead Sciences (GILD.O), opens new tab ... to make and sell cheaper copycat versions of its HIV prevention medicine in 120 low and lower-middle income countries.